Clinical trials: Immune System Tolerance
Microbiome, Cytokines
Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis
This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to…
- Conditions
- Microbiome, Cytokines, Plaque, Gingivitis
- Trial name
- NCT07501455
- Testing
- Distilled Water, Marketed Comparator 1, Marketed Comparator 2
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Kenvue Brands LLC
Healthy
A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China
1. To evaluate the tolerances of healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose 2.
- Trial name
- NCT03235778
- Testing
- Felbinac Trometamol Injection
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Yiling Pharmaceutical Inc.
Psoriasis, Pruritus
Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque Psoriasis, Dry Skin and Pruritus
The product RL3020-DP0364 developed by Pierre Fabre Laboratories moisturizes durably and repairs dry or atopic skin, especially in the case of certain dermatoses (atopic dermatitis, ichthyosis, etc ...) and erythema induced by…
- Conditions
- Psoriasis, Pruritus, Dry Skin
- Trial name
- NCT06800755
- Testing
- Dexeryl (RL3020-DP0364)
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Paraplegia, SCI
A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit
The ReWalk enables people with lower limb disabilities to carry out routine ambulatory functions (stand, walk, climb stairs etc.).
- Trial name
- RW (NCT00627107)
- Testing
- ReWalk - a motorized exoskeleton suit
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- ReWalk Robotics, Inc.
Enteral Feeding Intolerance
Retrospective Tube Feeding Tolerance in Adults With Intolerance After Switch to a Peptide-Based Formula
A retrospective chart review to assess feeding tolerance in adults who had been switched from an intact protein formula to a peptide-based formula due to feeding intolerance in a complex continuing care facility.
- Trial name
- RAP (NCT03048409)
- Testing
- Enteral Formula
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Société des Produits Nestlé (SPN)
HIV Infections
A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)
To assess the tolerance and toxicity profile of deoxy-3'-fluorothymidine (FLT) after multiple oral dosing for 16 weeks. To characterize the steady-state pharmacokinetics of FLT after multiple oral doses.
- Trial name
- NCT00002254
- Testing
- Alovudine
- Where
- 3 sites in United States
- Sponsor
- Lederle Laboratories
Varicose Ulcer
Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.
The main objective of this trial is to demonstrate that a local care strategy using URGO 310 3082 dressing is not inferior to a reference therapeutic strategy using a hydrofibre dressing in the management of venous ulcers.
- Trial name
- NCT01449422
- Testing
- Dressing
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Laboratoires URGO
Safety Issues
A Phase I Clinical Study of Hemay808
This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028.
- Trial name
- NCT04100642
- Testing
- Hemay808
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Yellow Fever Vaccine
VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)
The aim of this study is to compare the immunogenicity induced by yellow fever vaccination administered during pregnancy with that induced by vaccination outside pregnancy, and to assess the maternal and fetal tolerance of this…
- Trial name
- VAC-SIP-YF (NCT06694766)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Knee Osteoarthritis
Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis
The aim of this study is to assess the safety of Stemedica's mesenchymal stem cells in patients with knee osteoarthritis. The route of administration is intraarticular.
- Trial name
- NCT03602872
- Testing
- Human allogeneic mesenchymal bone marrow derived stem cells
- Where
- Mexico
- Sponsor
- Clinica Santa Clarita, Mexico
Lentigo, Hyperpigmentation
Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy
Pierre Fabre Dermo-Cosmétique has commercialized a cosmetic product (D-pigment rich texture) for treatment of hyperpigmentation.
- Trial name
- NCT03457246
- Testing
- D-Pigment rich texture, Hydrance optimale riche
- Volunteers
- 40 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Haemophilia A
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to evaluate safety of immune tolerance induction (ITI) treatment with turoctocog alfa (a recombinant factor VIII) in patients…
- Trial name
- NCT03588741
- Testing
- Turoctocog alfa
- Where
- 14 sites in Austria, Bulgaria and 5 more
- Volunteers
- 1 people
- Sponsor
- Novo Nordisk A/S
Safety Issues, Tolerance
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
This is a FIH, double-blind, placebo-controlled, within-group randomised, trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of compound 106 (C106) in…
- Conditions
- Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Trial name
- NCT05427253
- Testing
- C106 solution
- Where
- Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vicore Pharma AB
Cystic Fibrosis
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation.
- Trial name
- NCT02875366
- Testing
- LUM/IVA
- Where
- 12 sites in Australia, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Gastrointestinal Tolerance
Soy Formula Feedings in Healthy, Term Infants
This study evaluates the GI tolerance and acceptability of soy formulas fed to healthy term infants with reported intolerance to a milk-based formula.
- Trial name
- NCT02456831
- Testing
- Experimental Infant Formula 1, Experimental Infant Formula 2, Experimental Infant Formula 3
- Where
- 7 sites in United States
- Volunteers
- 115 people
- Sponsor
- Abbott Nutrition
Acute Myeloid Leukemia (AML)
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.
- Trial name
- NCT04402723
- Testing
- Donafenib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tyrosinemias, Alkaptonuria
Evaluation of TYR Sphere
For 28 days, 20 patients with tyrosinaemia will take TYR sphere as part of the usual dietary management of their condition. Patients will record their adherence to recommended intakes each day, gastrointestinal symptoms (if any)…
- Conditions
- Tyrosinemias, Alkaptonuria, Tyrosinemia, Type I, Tyrosinemia, Type II
- Trial name
- NCT04196959
- Testing
- TYR sphere
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Vitaflo International, Ltd
Growth
The Effects on Growth of a Non-Routine Infant Formula
A study to evaluate the growth and development of term infants fed either an extensively hydrolyzed formula with probiotics, a partially hydrolyzed formula with probiotics, or an extensively hydrolyzed formula without probiotics
- Trial name
- NCT00655720
- Testing
- infant formula
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
Gastroesophageal Reflux Disease, Reflux, Gastroesophageal
Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.
Current treatment for gastroesophageal reflux disease(GERD)confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric acid suppression.
- Trial name
- NCT00551473
- Testing
- Lavoltidine
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
To Evaluate
An Evaluation of Exercise Tolerance in Asthmatic Patients
To evaluate exercise tolerance.
- Trial name
- NCT01246154
- Testing
- EXERCISE TRAINING
- Where
- India
- Volunteers
- 15 people
- Sponsor
- Physio Care